Welcome to our dedicated page for Synlogic SEC filings (Ticker: SYBX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Synlogic, Inc. (SYBX) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, offering a structured view of its governance, compensation, financing and strategic decisions. As a biopharmaceutical company focused on Synthetic Biotic therapeutics, Synlogic uses these filings to report on corporate actions that shape its operations and capital structure.
Key documents for SYBX include annual proxy statements on Schedule 14A, which describe the agenda for stockholder meetings, board composition, executive and director compensation, equity incentive plans and voting procedures. For example, the company’s 2025 definitive proxy statement outlines proposals to elect directors, approve advisory votes on executive compensation, adopt the Synlogic, Inc. 2025 Equity Incentive Plan and ratify the appointment of KPMG LLP as independent registered public accounting firm.
Current reports on Form 8-K provide timely disclosure of material events. A December 15, 2025 Form 8-K details the results of the 2025 annual meeting, including stockholder approval of the 2025 Equity Incentive Plan, voting outcomes for director elections, advisory votes on named executive officer compensation and ratification of the independent auditor. Earlier 8-K filings and related documents can also reflect significant corporate developments such as restructuring actions, strategic reviews, adoption of stockholder rights plans and other events relevant to Synlogic’s evaluation of strategic alternatives.
On Stock Titan, these filings are paired with AI-powered summaries that highlight the most important points from lengthy documents, such as equity plan terms, changes in governance, or key risk and strategy disclosures. Users can quickly identify items related to equity compensation, stockholder voting, auditor selection and other governance matters without reading every page. Real-time updates from EDGAR ensure that new 10-K, 10-Q, 8-K, proxy and related filings for SYBX are captured as they become available, helping investors and researchers monitor how Synlogic’s corporate and financial reporting evolves alongside its strategic decisions.
Synlogic, Inc. filed an amended current report updating investors on its Nasdaq delisting and trading plans. The company withdrew its request for a Nasdaq hearing on January 16, 2026, and Nasdaq notified Synlogic that trading in its common stock would be suspended at the open of business on January 21, 2026, with a Form 25 to follow.
Synlogic states that, under Nasdaq rules, it believes it is a “public shell.” The company expects its common stock to be quoted on the OTC Markets Group, specifically the OTCQB Venture Market, and has submitted an application. Synlogic will remain a reporting company under the Exchange Act and does not expect the move to OTC to affect its business operations.
Synlogic, Inc. received a Schedule 13G reporting that investment entities affiliated with Baselake Partners, LP, including Baselake Management, LLC and individual investor David Paolella, beneficially own 1,140,000 shares of Synlogic common stock. This represents 9.7% of the outstanding common stock, based on the issuer’s report that 11,698,919 shares were outstanding as of November 6, 2025.
The shares are held by Baselake Partners, LP, with Baselake Management, LLC as investment manager and Paolella as managing member, and they report shared voting and dispositive power over all 1,140,000 shares and no sole voting or dispositive power. The filing states that the securities were not acquired and are not held for the purpose of changing or influencing control of Synlogic.
Synlogic, Inc. is voluntarily ending its effort to keep its common stock listed on The Nasdaq Capital Market after Nasdaq staff previously indicated they view the company as a “public shell.” The company withdrew its request for a Nasdaq hearings panel review, and Nasdaq has notified Synlogic that trading in its shares will be suspended at the open of business on January 21, 2026, with a Form 25 to follow to formally delist the stock. Synlogic expects its common stock to be quoted on the OTC Markets platform after delisting. The company states it will remain an SEC reporting company under the Securities Exchange Act of 1934 and that moving to OTC is not expected to affect its business operations, with further details on post-suspension trading to be disclosed when available.
Synlogic, Inc. held its 2025 annual meeting of stockholders on December 15, 2025, with a quorum of 10,292,327 shares, representing 87.97% of common stock outstanding as of the October 24, 2025 record date. Stockholders re-elected James Flynn and Richard P. Shea as Class I directors to serve until the 2028 annual meeting.
Stockholders approved, on a non-binding basis, the compensation of the company’s named executive officers and adopted the Synlogic, Inc. 2025 Equity Incentive Plan, which authorizes 1,000,000 shares of common stock plus 332,468 additional shares that may be issued if certain 2015 Plan awards are cancelled or expire. The prior 2015 Equity Incentive Award Plan is closed to new awards, while existing awards continue under their original terms. Stockholders also ratified KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2025.
Synlogic, Inc. (SYBX) filed its Q3 2025 report, highlighting a small operating footprint while pursuing strategic alternatives, including a possible merger or sale. The company recorded a net loss of $2.3 million for the quarter, driven largely by a $1.5 million loss from the change in fair value of purchase warrant liabilities.
Operating expenses were $1.0 million, reflecting minimal R&D activity after discontinuing the pivotal Synpheny‑3 trial in 2024 and completing a broad restructuring. Cash and cash equivalents were $15.6 million as of September 30, 2025, with management stating this is sufficient to fund operations for at least 12 months from the filing date. Stockholders’ equity stood at $10.3 million and purchase warrant liabilities at $5.3 million.
For the nine months, the company reported a net loss of $2.5 million, a significant improvement from the prior year due to restructuring completion and reduced operating costs. As of November 6, 2025, 11,698,919 shares were outstanding.
Synlogic, Inc. will hold its 2025 Annual Meeting on December 15, 2025 at 9:00 a.m. ET in a virtual-only format at www.virtualshareholdermeeting.com/SYBX2025. Stockholders can attend, submit questions, and vote online with their 16‑digit control number.
The agenda includes: (i) electing two Class I directors for three-year terms, (ii) an advisory vote on executive compensation, (iii) approval of the Synlogic, Inc. 2025 Equity Incentive Plan, and (iv) ratification of KPMG LLP as independent registered public accounting firm for fiscal year 2025. The Board recommends voting FOR all proposals.
The record date is October 24, 2025, with 11,698,919 shares of common stock outstanding and entitled to vote. Voting is available via Internet, telephone, mail, or during the live webcast. Brokers may exercise discretion to vote only on the auditor ratification item (Proposal 4) absent instructions.
Synlogic (SYBX) insider transaction: Principal Executive and Financial Officer Mary Beth Dooley reported a sale of common stock. On October 29, 2025, she sold 157 shares at $1.81 per share.
The filing states the shares were sold to cover tax liabilities arising from a restricted stock award that vested on October 28, 2025 from a 2022 grant. Following the sale, she beneficially owned 12,744 shares directly. This appears to be routine tax withholding related to equity vesting rather than an open‑market discretionary sale.
Synlogic, Inc. filed an amended shelf registration statement on Form S-3/A (ticker SYBX) containing an exhibit index listing charter amendments, bylaws, stock certificate form, indentures, warrant/unit/rights forms, legal opinions, auditor consents, a trustee eligibility statement and a filing fee table. Several certificates of amendment are dated June 15, 2023 and September 27, 2023. The filing shows signatures by company officers and directors dated August 15, 2025.
Synlogic, Inc. (SYBX) filed a shelf registration on Form S-3 to offer up to $150,000,000 of securities, including common stock, preferred stock, debt and warrants. The company reported that it discontinued Synpheny-3, the pivotal Phase 3 study of its lead candidate labafenogene marselecobac (SYNB1934), in February 2024 after an internal review indicated the trial was unlikely to meet its primary endpoint, and stated the decision was not based on safety or tolerability concerns.
Management says its strategy now prioritizes strategic alternatives to enhance stockholder value, including a potential merger or sale, while earlier-stage programs remain in development, notably SYNB1353 which achieved proof of mechanism in a Phase 1 study. The prospectus notes the common stock trades on Nasdaq under SYBX, with 11,698,919 shares outstanding as of August 6, 2025 and a last reported sale price of $1.39 on August 7, 2025.